Do psychological interventions reduce symptoms of depression for patients with Bipolar I or II Disorder? A meta-analysis

Sakir Yilmaz<sup>1,\*</sup>, Anna Huguet<sup>2,3,4</sup>, Steve Kisely<sup>2,5,6</sup>, Sanjay Rao<sup>7</sup>, JianLi Wang<sup>8</sup>, Kayti Baur<sup>9</sup>, Molly Price<sup>10</sup>, Heather O`Mahen<sup>1</sup>, Kim Wright<sup>1</sup>

<sup>1</sup> University of Exeter Department of Psychology

<sup>2</sup> Dalhousie University, Department of Community Health and Epidemiology

<sup>3</sup> Universitat Rovira I Virgili Departament de Psicologia

<sup>4</sup> IWK Health Centre

<sup>5</sup> University of Queensland, Psychiatry

<sup>6</sup> Metro South Addiction and Mental Health Epidemiology Service

<sup>7</sup> University of Ottawa Faculty of Medicine, Psychiatry

<sup>8</sup> University of Ottawa, School of Epidemiology, Public Health and Preventive Medicine,

Department of Psychiatry

<sup>9</sup> Dalhousie University

<sup>10</sup> Cardiff University, Psychology

\* Corresponding author: University of Exeter Department of Psychology, Washington Singer Labs., Perry road, Exeter EX4 4QG, U.K. <u>sy351@exeter.ac.uk</u>

## Abstract

**Background:** Psychological therapies may play an important role in the treatment of bipolar disorders. Several meta-analyses that examine the effectiveness of psychotherapies for patients with bipolar disorder include conclusions about the impact upon bipolar depression. However, these tend not to consider differences in depression outcome depending upon whether the therapy primarily targets acute depression, nor severity of baseline depression. This may affect the conclusions drawn about the effectiveness of these therapies for acute bipolar depression treatment.

**Objectives:** This meta-analysis explored the effectiveness of psychological therapies in reducing bipolar depression, in particular examining whether: (1) the effect of therapy is greater when baseline depressive symptoms are more severe, and (2) the effect of therapy is greater when the primary focus of the therapy is the treatment of acute bipolar depression?

**Data sources:** A systematic search was conducted using the following electronic databases; Cochrane Controlled Register of Trials (1996), MEDLINE (1966 onwards), EMBASE (1980 onwards), PsycINFO (1974 onwards), Scopus, Web of Science and Clinical Trials Registries (listed at:https://www.hhs.gov/ohrp/international/clinical-trial-registries/index.html). **Eligibility criteria:** Eligible studies were randomized controlled trials evaluating a psychological intervention for adults diagnosed with Bipolar I or II disorder. The comparators were usual care, wait-list, placebo, active treatment control. Post-treatment depression status was required to be measured continuously using a validated self- or observer- report measure, or categorically by a validated diagnostic instrument or clinical diagnosis by a suitably qualified person.

**Data extraction and synthesis:** Titles and abstracts were screened, followed by full texts. Two reviewers conducted each stage until agreement was reached, and both independently extracted study information. Means, standard deviations (SDs) and number of participants were retrieved from articles and used to perform a meta-analysis. The primary outcome was depressive symptom score.

**Results:** The database search identified 6388 studies. After removing the duplicates, 3298 studies remained, of which, 28 studies were included in the qualitative review and 22 in the meta-analysis. Effect sizes range from -1.99 [-2.50, -1.49] to 0.89 [-0.12, 1.90]. There was low quality evidence of a significant effect on symptoms of depression for cognitive behavioural therapy and dialectical behaviour therapy. Trials of psychoeducation, mindfulness-based therapy, family therapy and interpersonal and social rhythm therapy showed no evidence of any effect on depression. We found no significant relationship between baseline depression score and depression outcome post-treatment when we controlled for therapy type and comparator. The result also showed that the effect size. *Conclusions:* Some psychological therapies may reduce acute bipolar depression although this conclusion should be viewed with caution given the low quality of evidence. More research using similar therapy types and comparators is needed to better understand the relationship between depression status at baseline and outcome.

Key words: Bipolar depression, psychological interventions, meta-analysis

### 1. Introduction

Bipolar disorders are a category of chronic and recurrent psychiatric disorder with severe mood shifts from mania to depression. The disorders are associated with a shorter life expectancy (Laursen, 2011; Crump et al., 2013) and both psychiatric (Vieta et al., 2001; Krishnan et al., 2005) and medical (McIntyre et al., 2006; Kemp et al., 2010; Crump et al., 2013) comorbidity. Bipolar disorders affect about 1-2% of the population (Merikangas et al., 2011), with the majority of individuals experiencing multiple episodes of mania/hypomania and depression over a lifetime. Though mania and hypomania are particularly characteristic of bipolar disorder, the long-term course of a bipolar disorder is dominated by depressive symptoms (Judd et al., 2002; Perlis et al., 2006; Judd and Akiskal, 2003). These symptoms are associated with an increased risk of suicide attempts and completed suicide (Rihmer et al., 1990; Eroglu, Karakus & Tamam, 2013; Tidemalm et al., 2014), as well as comorbid anxiety in the form of panic attacks (Pini et al., 1997).

Psychological therapies may play an important role in the treatment of bipolar disorders. These include cognitive-behavioral therapy (CBT), psychoeducation, family focused therapy, interpersonal and social rhythms therapy (IPSRT), mindfulness-based cognitive therapy (MBCT), and dialectical behavior therapy (DBT). However, with respect to bipolar depression, findings from previous meta-analyses have been mixed. For example, Beynon et al. (2008) and Oud et al. (2016) reported that CBT could improve depressive symptoms, while Bi-Yu et al. (2016) did not find this. Similarly, in the case of psychoeducation, Oud et al. (2016) reported fewer depressive relapses following group therapy while Bond and Anderson (2015) found no effect. We propose that one possible explanation for this inconsistency is that the impact of therapy on depression may vary according to the primary target of the therapy protocol, such that therapy protocols that actively address depression as the target difficulty may be more likely to show an effect on depression than studies targeting a different difficulty. Furthermore, impact upon depression outcomes may be a function of baseline depression levels, because studies in which participants have higher levels of depression at baseline have greater potential to show an effect of the intervention upon depression.

Our aim was to answer whether psychological interventions for patients with Bipolar I or II Disorder reduce symptoms of depression, compared to usual care, wait-list, placebo or active control in randomized controlled trials, and whether intervention target, pretreatment depression status, therapy modality, group versus individual therapy or psychological comorbidity at baseline affect treatment outcomes. We explored whether the effect was greater for studies including participants with higher levels of depression at baseline and for studies in which the therapy protocol primarily targeted acute depression as opposed to other difficulties. No other hypothesis were stated for the rest of the goals.

## 2. Methods

### 2.1. Protocol and registration

Our study protocol was registered on the PROSPERO database (CRD42019133442). Our report is written in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline.

#### 2.2. Eligibility criteria

Inclusion criteria were:

- Randomised controlled trials (RCT) evaluating the efficacy or effectiveness of a psychological intervention for adults diagnosed with Bipolar I or II disorder using a validated diagnostic instrument (SCID, SADS, CIDI, PSE-10 SCAN, and MINI) or according to clinical diagnosis by a suitably qualified person.
  Psychological interventions were defined broadly: "interpersonal or informational activities, techniques, or strategies that target biological, behavioral, cognitive, emotional, interpersonal, social, or environmental factors with the aim of improving health functioning and well-being" (Darke, 2016). "Randomised" was defined as the study reporting use of random allocation of participants to conditions: we did not specify randomisation method required, however this considered within in risk of bias assessment. We did not place restrictions upon whether or not the psychological intervention should be adjunctive (i.e. delivered in addition to ongoing medication as part of usual care).
- Studies using as a control condition one of the following: treatment / care as usual, wait-list, active control, and placebo. In keeping with standard definitions used by the Cochrane database (Faltinsen et al., 2019), usual care was defined as an intervention that reflects locally accepted treatment practices for individuals with bipolar disorder. Wait list was defined as receiving the experimental intervention after the trial ended. Active treatment defined as provision of a comparator psychological treatment that was not intended to replicate standard local care, nor to simply control for non-specific or shared factors. Psychological placebo was defined as an intervention that targets the nonspecific or shared components of psychological treatments.
- Studies using as a treatment outcome depression symptom level assessed at pre and post-treatment, and measured either through researcher/clinician rating, using either a continuous or categorical scale.
- Studies investigating participants aged 16 and above.
- Studies published in English.
- Studies published between 1952 and 2020.

## 2.3. Search strategy

The search strategy included terms for bipolar disorders (e.g., mania; manic depression), depression (e.g., depressive), therapy (e.g., psychotherapy; behav\* activation), and randomized control trials (e.g., random allocation; randomisation). These were used to determine subject headings unique to each database. The following were searched up to an including end date of October 2020: Cochrane Controlled Register of Trials (1996), MEDLINE (1966 onwards), EMBASE (1980 onwards), PsycINFO (1974 onwards), Scopus, Web of Science and Clinical Trials Registries (listed

at:https://www.hhs.gov/ohrp/international/clinical-trial-registries/index.html) (search terms for MEDLINE in the Supplement).

In addition, the reference lists of relevant systematic reviews and meta-analyses were examined for potentially eligible studies. We contacted protocol authors for further information when we were unable to find any corresponding outcome studies.

### 2.4. Study selection

All studies retrieved were compiled in EndNote software. After duplicates were removed both automatically and manually, two reviewers (SY, KB) independently screened a random set of 20% of titles/abstracts retrieved by the search strategy, at which point agreement between reviewers was calculated (Kappa = .82). Discrepancies between reviewers were discussed between the two reviewers and resolved, with input from a third reviewer (AH) as required. When agreement was reached, the remaining studies were screened by one reviewer (SY). Once the full list of titles/abstracts was screened, the full text of potentially eligible studies was retrieved. For those studies for which we could not find the full-text article, study authors were contacted to request the article. Fifteen out of 17 requested articles were provided from study authors. Two reviewers (SY, KB) screened full articles following the same procedure as previously. A third reviewer (AH) involved was involved when discrepancies occurred.

#### 2.5. Data extraction

A data extraction sheet was developed and pilot tested by two reviewers (SY and AH) using one randomly selected study. Data from included studies were then extracted with the extraction form. Two reviewers (SY, KB) independently extracted the information for all studies included in the review. Discrepancies between reviewers were discussed between them and resolved. A third reviewer (AH) was involved when an agreement could not be reached. For those studies for which we could not extract necessary information, study authors were contacted to request it. Requested information was provided by 4 study authors out of 8.

The following data were extracted: authors, year of publication, sample size, country in which the trial was conducted, study criteria, primary diagnosis, psychiatric comorbid conditions, target participants' age, study setting (i.e., clinical setting, general population), research design, number of arms, type of comparison group (i.e., usual care, placebo, wait list, and another active treatment), intervention target (i.e., acute depression, remission), depression status, person who delivered the intervention and control, number of individuals at baseline, length of follow-up, total number of drop outs from baseline to last follow-up, duration of treatment, type of psychological treatment (i.e., CBT, IPT, behavioural therapy, psychoeducation, psychodynamic therapy, family therapy, counselling, mindfulness therapy, other), treatment modality (self-help, individual face-to-face therapy, group therapy, online/e-supported), treatment outcome variables, treatment outcome measures, type of outcome (continuous/categorical) and for each treatment outcome and each assessment time point: number of cases and number of events for categorical variables.

We extracted data at two follow-up points: post-treatment and longer-term follow-up. Post-treatment depression outcome was defined as the point immediately following the end of the acute treatment phase, and no later than 3 months after the end of treatment. Longer term outcomes were defined as being between the post-treatment outcome point and 18 months after the end of the treatment phase.

#### 2.6. Quality of Evidence

The quality of selected studies were assessed independently at study level by two reviewers (SY, MP) using the Cochrane Collaboration's risk of bias tool (Higgins et al., 2011). A third reviewer (AH) involved was involved when discrepancies were found. The following items were assessed: selection bias (random sequence generation and allocation concealment); performance bias (blinding of participants and personnel); detection bias (blinding of outcome assessment); attrition bias (incomplete outcome data); reporting bias (selective reporting); and other bias (intention to treat analysis and group similarity at baseline, checks of the training of the therapist, manualisation of the therapy and whether fidelity to the therapy method had been assessed through rating tapes of all or only a subset of sessions). A judgement about the risk of bias arising from each item was made for each study. The judgement could be: low, unclear, or high risk of bias.

The Grading of Recommendations Assessment, Development and Evaluation (GRADE, 2013) framework was used to assess the overall quality of evidence for each outcome where it was possible to estimate a pooled effect. The GRADE approach categorizes the levels of the quality as very low, low, moderate, and high by utilizing several domains. According to this framework, quality rating is reduced by the presence of study limitations, inconsistency, indirectness, imprecision, and publication/reporting bias. One reviewer (KW) with subject matter expertise graded the overall quality of evidence using the GRADE framework, with decisions checked by a second reviewer (SY).

### 2.7. Data synthesis

Data such as means, standard deviations (SDs) and number of participants were retrieved from articles and used to perform a meta-analysis. The primary outcome was depressive symptom score. A meta-analysis was conducted using RevMan software, with pooled results expressed as the standardized mean differences (SMD) and associated 95% confidence intervals (95% CI). Standardized mean differences were calculated as our effect-size measure, which is the difference in post-treatment means divided by the pooled standard deviation, with adjustment for small sample bias (i.e. weights). A random-effects model was used and assumed common heterogeneity across all comparisons.

To examine the presence of heterogeneity, we used the I<sup>2</sup> statistic, which estimates the percentage of outcome variability that can be attributed to heterogeneity across studies. An I<sup>2</sup> value of 0% denotes no observed heterogeneity, whereas, 25% is "low", 50% is "moderate" and 75% is "high" heterogeneity (Higgins et al., 2003). Publication bias was assessed through use of Egger's linear regression model to statistically test for funnel plot asymmetry.

Pre-specified sensitivity analyses and/or meta-regression were conducted using Open Meta-Analyst software. As primary sensitivity analyses, we examined the relationship between the following: i) intervention target (acute depression / relapse prevention / comorbid condition [i.e. anxiety, substance use, cognitive functioning]) and depression outcome; ii) depression status at pre-treatment and outcome. To examine the impact of intervention target, we grouped studies as follows: i) those that primarily and explicitly set out to treat acute depression; ii) those that set out primarily to prevent relapse; iii) those that set out to improve quality of life (only studies targeting relapse prevention and quality of life were present in sufficient numbers to allow this sensitivity analysis). To examine the impact of depression status pre-treatment upon outcome, we operationalised depression status in two ways: i) whether or not current acute depression was a stated inclusion criterion of the study; ii) mean depression score for study participants at pre-treatment. Additional secondary sensitivity analysis explored the relationship between outcome and: i) modality of therapy ii) group versus individual therapy, iii) psychological comorbidity at baseline. To reduce heterogeneity and to reflect that our extracted studies included a range of psychological therapy approaches, subgroup analyses were conducted by splitting interventions into psychoeducation, CBT, MBCT, other therapies (DBT, family therapy, and IPSRT) for post-treatment and follow up. In addition, further subgroup analyses were conducted by examining studies within each intervention type according to the control condition used.

## 3. Results

We identified a total of 6388 studies through database searches and reference lists of relevant systematic reviews and meta-analyses. Of these, we removed 3298 duplicates automatically and manually (Figure 1). A further 3078 studies were excluded after title and abstract screening and as they were not randomized control trials. We then assessed 220 studies in full-text review for eligibility and of these, we excluded 188 studies as they did not meet the inclusion criteria. The remaining 32 studies were therefore included in our qualitative review. Of these, 22 were included in the meta-analysis (figure 1). The remaining 10 trials could not be included as the required outcomes were neither available in the article, nor from study authors.

### 3.1. Study characteristics

Six types of psychological therapies were identified: CBT, psychoeducation, DBT, MBCT, family therapy, and IPSRT. Studies were conducted in 11 countries: Australia, USA, Iran, UK, China, Spain, Egypt, France, Taiwan and New Zealand. Recruitment was from out-patient (21) and in-patient settings (1). For 6 studies, the information provided relating to study settings was unclear. Eleven studies examined CBT (3 group therapy, 8 individual face to face therapy); 13 psychoeducation (9 group therapy, 2 individual face to face therapy, 2 Online / e supported); 1 DBT (group therapy); 2 MBCT (group therapy); 1 family therapy (group therapy); 1 IPSRT (other). Control groups consisted of treatment as usual (16), waiting list (2), placebo (8), active control (2). In each study, the total number of participants ranged from 20 to 304. Overall follow-up ranged from 0 to 60 months. Duration of acute treatment ranged from 4 to 36 months (see Table 1 for further details).



Table 1 Summary of the characteristics of the included studies	

Studies, country	Primary diagnosis	Study setting	Primary intervention target	Depressio n status at baseline	Number of individuals randomize d	Length of follow- up (in month s	Duration of acute treatmen t (in weeks)	Duration of treatmen t sessions (in minutes)	Number of treatmen t sessions	Treatmen t outcome measure	Treatment group	Treatmen t modality	Comparato r group
D'Souza 2010, Australia	Bipolar disorder (NOS)	Outpatient	Relapse prevention	Not depressed	58	12	12	90	12	MADRS	Psychoeducatio n	Group therapy	Usual care
Costa 2011, Brazil	Bipolar disorder (NOS)	Outpatient	Unclear/Unspecifie d	Not depressed	41	Up to 6	14	120	14	BDI	СВТ	Group therapy	Usual care
Schmitz 2002, Texas	Bipolar disorder (NOS)	Outpatient	Relapse prevention	Not specified	46	N/A	12	60	16	BDI	СВТ	Individual face to face therapy	Placebo
Dijk 2013, Canada	Bipolar disorder NOS)	Outpatient	Unclear/Unspecifie d	Not specified	26	N/A	12	90	12	BDI-II	DBT	Group therapy	Waiting list
Deckersbac h 2018, USA	Bipolar I disorder	Unclear/Unspecifie d	Acute depression	Depressed	32	4	20	50	18	HDRS	CBT	Individual face to face therapy	Placebo
Weiss 2007, JSA	Bipolar disorder (NOS)	Outpatient	Other	Not specified	62	3	20	60	20	HDRS	СВТ	Group therapy	Active control
Perich 2013, Australia	Bipolar disorder (NOS)	Outpatient	Relapse prevention	Not depressed	95	12	8	120-150	8	MADRS	MBCT	Group therapy	Usual care
Miklowitz 2000, USA	Bipolar I disorder Bipolar	Inpatient	Relapse prevention	Not specified	101	3	36	60	21	SADS-S	Psychoeducatio n	Group therapy	Usual care
aridhossei ni 2017,Iran	disorder (NOS)	Outpatient	Quality of life	Not depressed	26	6	4	60	8	HDRS	Psychoeducatio n	Group therapy	Usual care

Lam 2000, Uk	Bipolar I disorder	Outpatient	Relapse prevention	Not depressed	25	6	24	Not stated	12-20	BDI	CBT	Individual face to face therapy	Usual care
Faria 2014, Brazil	Bipolar II disorder	Outpatient	Other	Not specified	61	N/A	6	60	6	HDRS	Psychoeducatio n	Individual face to face therapy	Usual care
Smith 2011 <i>,</i> Uk	Bipolar disorder (NOS)	Outpatient	Quality of life	Not depressed	50	6	16	Not stated	8	MADRS	Psychoeducatio n	Online / e supporte d	Usual care
Morriss 2016, Uk	Bipolar disorder (NOS)	Unclear/Unspecifie d	Unclear/Unspecifie d	Not depressed	304	24	26	120	21	GRID- HDRS	Psychoeducatio n	Group therapy	Placebo
Castle 2007, Australia	Bipolar disorder (NOS)	Outpatient	Relapse prevention	Not specified	20	3	12	90	15	MADRS	Psychoeducatio n	Group therapy	Placebo
Weiss 2009 <i>,</i> USA	Bipolar disorder (NOS)	Outpatient	Other	Not specified	61	3	12	60	12	HDRS	CBT	Group therapy	Usual care
Lam 2003, Uk	Bipolar I disorder	Outpatient	Relapse prevention	Not depressed	103	6	24	60	12-18	BDI	CBT	face to face face	Usual care
Castle 2010, Australia	Bipolar disorder (NOS)	Outpatient	Relapse prevention	Not depressed	84	9	12	90	12	MADRS	Psychoeducatio n	Group therapy	Usual care
Isasi 2010, Spain	Bipolar I disorder	Outpatient	Unclear/Unspecifie d	Not depressed	40	12	20	90	20	BDI	CBT	Individual face to face therapy	Usual care
Cardoso 2014, Brazil	Bipolar disorder (NOS)	Outpatient	Quality of life	Not specified	61	6	6	60	6	HDRS	Psychoeducatio n	Individual face to face therapy	Usual care
Zaki 2014, Egypt	Bipolar disorder (NOS) Bipolar	Outpatient	Unclear/Unspecifie d	Not specified	111	3	36	90-120	21	HDRS	Psychoeducatio n	Group therapy	Active control
Ball 2006, Australia	disorder (NOS)	Outpatient	Relapse prevention	Not depressed	52	12	20	60	20	BDI	CBT	Individual face to	Usual care

												therapy	
Miklowitz 2007, USA	Bipolar disorder (NOS)	Outpatient	Acute depression	Depressed	293	3	36	50	Up to 30	MADRS	CBT, family therapy, IPSRT	Individual face to face therapy	Placebo
Docteur 2020, France	Bipolar I disorder	Outpatient	Acute depression	Not specified	99	N/A	8	120	8	BDI-13	MBCT	Group therapy	Waiting list
Gliddon 2018, Australia	Bipolar disorder (NOS)	Unclear/Unspecifie d	Acute depression	Not specified	304	12	10	Not stated	10	MADRS	Psychoeducatio n	Online / e supporte d Individual	Placebo
Jones 2019, Uk	Bipolar disorder (NOS)	Unclear/Unspecifie d	Other	Not specified Not	44	6	24	45-60	24	HAM-D	СВТ	face to face therapy	Usual care
Lin 2020, Taiwan	Bipolar disorder (NOS)	Outpatient	Other	specified	68	6	24	90	24	HAMD-17	Psychoeducatio n	Group therapy	Usual care
Porter 2019, New Zelland	Bipolar disorder (NOS)	Unclear/Unspecifie d	Other	specified	100	18	24	Not stated	24	MADRS	IPSRT	Other	Placebo
Chen, 2018	Bipolar I disorder	Inpatient	Relapse prevention	Not specified	140	12	2	40-60	8	HDRS	Psychoeducatio n	Group	Placebo

face

Note. NOS, Not otherwise specified; CBT, Cognitive Behavior Therapy; IPSRT, and Interpersonal and Social Rhythm Therapy; MADRS, Montgomery-Asberg Depression Rating Scale; BDI, Beck Depression Inventory; BDI-II, Beck Depression Inventory II; BDI 13, Beck Depression Inventory 13; HDRS, Hamilton Depression Rating Scale; GRID HDRS, GRID Hamilton Depression Rating Scale; HADS, Hospital Anxiety and Depression Scale; HAM-D, Hamilton Depression Rating Scale; HAMD-17, Hamilton Depression Rating Scale 17

## Table 2 GRADE evidence profile

	Quality asses	sment				Summary of Finding					
	Risk of bias	Inconsistency	Indirectness	Imprecision	Publication bias	Number of Individuals	Comparator	Quality			
Psychoeducation	Serious limitations	Substantial heterogeneity	Very serious	No serious	Undetected	603	443	Low			
СВТ	Serious limitations	No evidence of significant heterogeneity	Very serious	No serious	Evidence for publication bias	403	211	Low			
DBT	Serious limitations	Not applicable	Very serious	Very serious	Not applicable	12	12	Low			
МВСТ	Serious limitations	Possible moderate heterogeneity	Very serious	Very serious	Not applicable	110	84	Low			
FT & IPSRT	Serious limitations	Not applicable	No serious	Very	Not applicable	59	60	Low			
Psychoeducation versus usual care	Serious limitations	No evidence of significant heterogeneity	Very serious	No serious	Undetected	204	235	Low			
Psychoeducation versus placebo	No serious limitations	No evidence of significant heterogeneity	Very serious	No serious	Not applicable	352	176	Moderate			
Psychoeducation versus active control	Serious limitations	Not applicable	Very serious	Very serious	Not applicable	67	32	Low			
CBT versus usual care	Serious limitations	No evidence of significant heterogeneity	Very serious	No serious	Evidence for publication bias	157	133	Low			
CBT versus placebo	Serious limitations	No evidence of significant heterogeneity	No serious	No serious	Evidence for publication bias	246	78	Low			
MBCT versus usual care	Serious limitations	Not applicable	Very serious	Very serious	Not applicable	48	47	Low			
MBCT versus waiting list	Serious limitations	Not applicable	No serious	Very serious	Not applicable	62	37	Low			

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (selection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Intention to treat analysis (other bias)	Group similarity at baseline (other bias)	Manualization (other bias)	Training (other bias)	Fidelity (other bias)
D'Souza 2010	•	?	?	+	•	?	+	+	•	+	?
Costa 2011	?	?	?	?	+	?	÷	+	+	?	?
Schmitz 2002	•	?	?	?	ē	?	?	ŧ	÷	+	+
Dijk 2013	?	÷	•	?	+	?	?	+	?	?	+
Deckersbach 2018	÷	?	•	?	•	?	Ŧ	•	÷	?	?
Weiss 2007	?	÷	?	•	ē	?	ŧ	?	•	?	+
Perich 2013	Ŧ	+	•	+	ē	?	ŧ	+	•	+	+
Miklowitz 2000	?	?	?	?	ē	?	ŧ	+	+	+	+
Faridhosseini 2017	+	•	?	?	+	?	•	÷	•	?	?
Lam 2000	?	?	?	+	•	?	+	•	?	+	?
Faria 2014	+	+	?	÷	•	?	ŧ	+	÷	+	?
Smith 2011	÷	?	?	+	•	?	•	÷	÷	?	?
Morriss 2016	÷	+	?	+	•	+	÷	+	•	+	+
Castle 2007	÷	?	•	+	+	?	ŧ	+	+	+	?
Weiss 2009	?	?	?	?	+	?	÷	+	•	?	+
Lam 2003	ŧ	+	?	?	÷	?	ŧ	+	÷	?	+
Castle 2010	÷	+	•	?	+	?	•	+	+	+	+
Isasi 2010		+	?	+	?	?	Ŧ		+	?	?
Cardoso 2014	÷	+	•	?	•	?	ŧ	+	+	?	?
Zaki 2014	?	?	?	?	?	?	Ŧ	+	+	?	?
Ball 2006	+	?	?	?	•	?	ŧ	+	+	+	+
Miklowitz 2007	+	?	?	?	•	?	Ŧ	?	+	+	+
Docteur 2020	?	?	?	?	?	?	?	+	+	?	?
Gliddon 2018	+	+	•	+	+	?	+	+	?	?	?
Jones 2019	+	+	•	+	?	+	?	+	+	+	+
Lin 2020	+	?	?	?	+	+	+	+	+	?	?
Porter 2019	+	+	?	+	?	?	?	+	+	?	?
Chen 2018	+	+	?	+	+	?	?	+	+	+	?

Figure 2. Cochrane risk of bias assessment for RCTs

## 3.2. Study quality (Risk of Bias)

Figure 2 shows the risk of bias assessment for each RCT. Three studies were at high risk of bias for random sequence generation, whereas it was not sufficiently reported in 8 of the 28 studies that were included. Only one study (Faridhosseini 2017) was at high risk of bias for allocation concealment while it was not sufficiently reported in 14 studies. Blinding of participants and personnel was not possible in 8 studies, while it was unclear for the rest. High risk of bias for detection bias was found in only one study (Weiss 2007), although detection bias was not reported sufficiently in more than half of the studies. Nineteen studies employed intention-to-treat analysis, whereas only three studies used per protocol analysis. Two studies were at high risk of bias for group similarity at baseline. Three studies were at low risk of bias for selective reporting, whereas the rest were unclear. More than two third of studies were at low risk of bias for manualization. Thirteen studies were at low risk of bias for training, although the rest were unclear.

Overall, the quality of studies was low, other than for studies examining psychoeducation versus placebo, in which the quality was moderate.

## 3.3. Post-treatment effects

After extracting the data, we decided to use continuous depression score as the outcome variable in our meta-analysis as only two studies reported a categorical variable, whilst all reported a continuous variable.

### 3.3.1. Psychoeducation

It was possible to combine data for comparisons with usual care and placebo only. There were 1046 participants from 12 RCTs of psychoeducation who were identified through the search and included in the analysis. Psychoeducation was not found to be superior to either usual care or placebo, (Figure 3). There was a significant effect in a study that compared psychoeducation with active control (Zaki 2014; z = 7.70, p < 0.00001, SMD = -1.99 [95% Cl -2.50, -1.49]).

## 3.3.2. CBT

There were 614 participants from 8 RCTs of CBT. Intervention was compared with usual care and placebo. Treatment modalities were group therapy and individual face-to-face therapy. There was a significant effect for comparison with usual care (figure 4). The degree of heterogeneity was low (p = 0.31,  $I^2 = \%15$ ). All outcomes from studies of CBT comparing usual care were in favour of intervention.

## 3.3.3. MBCT

There were 194 participants from 2 RCTs (n= 194) of MBCT, compared with usual care and waiting list. Treatment modality was group therapy. The degree of heterogeneity was moderate (p = 0.17,  $I^2 = 47\%$ ). There was a significant effect in the study that compared with usual care (z = 2.25, p = 0.02, SMD = -0.47 [95% CI –0.88, -0.06]) but not in the study comparing to waiting list (z = 0.31, p = 0.75, SMD = -0.07 [95% CI –0.47, 0.34]).

## 3.3.4. Other therapies

There were 24 participants from 1 RCT of DBT, 49 participants from 1 RCT of family therapy, and 72 participants from 1 RCT of IPSRT who were identified through the search.

Although intervention was compared with waiting list for DBT, intervention was compared with placebo for other two interventions. Treatment modality was group therapy for all. There was a significant effect of DBT on symptoms of depression at post-treatment (z = 2.63, p = 0.009, SMD = -1.18 [95% CI -2.06, -0.30]). The effect was not significant for family therapy (z = 0.14, p = 0.89, SMD = -0.04 [95% CI -0.62, 0.53]) nor for IPSRT (z = 0.63, p = 0.53, SMD = -0.15 [95% CI -0.62, 0.32]).

	Inte	rventio	on	C	ontrol			Std. Mean Difference	Std. Mean Difference				
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl				
1.2.1 Psychoeducation	on versu	IS USUA	al care										
Cardoso 2014	<mark>9.41</mark>	5.56	19	10.86	5.7	26	10.3%	-0.25 [-0.85, 0.34]					
Castle 2010	10.6	7.6	32	9.4	8.5	40	16.6%	0.15 [-0.32, 0.61]					
D'Souza 2010	2.7	5.6	26	3.6	6.5	27	12.5%	-0.15 [-0.69, 0.39]					
Faria 2014	12.53	6.14	32	12.62	5.49	29	14.3%	-0.02 [-0.52, 0.49]					
Faridhosseini 2017	8.25	5.59	12	5.83	3.32	12	5.5%	0.51 [-0.31, 1.32]					
Lin 2020	7.08	<mark>4.7</mark>	38	9.5	6.29	30	15.4%	-0.44 [-0.92, 0.05]					
Miklowitz 2000	2	0.8	28	<mark>2.4</mark>	1	51	16.6%	-0.42 [-0.89, 0.04]					
Smith 2011	9.1	8.4	17	11.1	13.6	20	8.7%	-0.17 [-0.82, 0.48]					
Subtotal (95% CI)			204			235	100.0%	-0.15 [-0.34, 0.05]	•				
Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 7.14, df = 7 (P = 0.41); l <sup>2</sup> = 2%													
Test for overall effect:	Z=1.49	(P = 0	.14)										
400D		anna <b>i</b> ana											
1.2.3 Psychoeducatio	on versu	is plac	epo						1 m				
Castle 2007	<mark>13</mark>	7.3	8	<u>5.8</u>	8	9	9.9%	0.89 [-0.12, 1.90]					
Gliddon 2019	9.9	7.7	202	12	9.2	48	42.0%	-0.26 [-0.58, 0.05]	-				
Morriss 2016	7	7.17	122	8.18	7.26	119	48.0%	-0.16 [-0.42, 0.09]					
Subtotal (95% CI)			332			176	100.0%	-0.10 [-0.45, 0.25]	•				
Heterogeneity: Tau <sup>z</sup> =	0.05; Cl	ni² = 4.	53, df =	: 2 (P =	0.10);	<sup>2</sup> = 569	6						
Test for overall effect:	Z = 0.57	(P = 0	.57)										
									-4 -2 0 2 4				
									Favours (intervention) Favours (control)				
Test for subgroup diff	erences	: Chi <sup>2</sup> =	= 0.05,	df = 1 (F	9 = 0.8	2),   <sup>2</sup> = I	0%		· ····································				

Figure 3. Forest plot of post-treatment depression outcome for Psychoeducation versus different comparators

	Inte	rventio	on	C	Control			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
1.3.1 CBT versus us	ual care								
Ball 2006	6.6	6.76	21	13.32	10.39	16	12.3%	-0.77 [-1.45, -0.10]	
Costa 2011	7.24	6.42	27	13.92	9.17	12	11.1%	-0.89 [-1.60, -0.18]	
Isasi 2010	8.6	5.95	20	12.7	10.28	20	14.2%	-0.48 [-1.11, 0.15]	
Lam 2000	6.18	8.44	12	11.56	13.88	11	<mark>8.2%</mark>	-0.46 [-1.29, 0.37]	
Lam 2003	8.2	7.9	46	13.2	14.7	44	32.2%	-0.42 [-0.84, -0.00]	
Weiss 2009	8.4	6.7	31	11	8	30	22.0%	-0.35 [-0.85, 0.16]	
Subtotal (95% CI)			157			133	100.0%	-0.51 [-0.75, -0.27]	•
Heterogeneity: Tau <sup>z</sup> =	= 0.00; C	hi² = 2.	.27, df=	= 5 (P =	0.81); l <sup>a</sup>				
Test for overall effect	Z = 4.23	) (P < C	).0001)						
1.3.2 CBT versus pla	cebo								1
Gliddon 2019	11.6	10.2	202	12	9.2	<mark>48</mark>	68.6%	-0.04 [-0.35, 0.27]	
Miklowitz 2007	14.61	9.46	44	16.25	10.71	30	31.4%	-0.16 [-0.63, 0.30]	
Subtotal (95% CI)			246			78	100.0%	-0.08 [-0.34, 0.18]	•
Heterogeneity: Tau <sup>2</sup> =	= 0.00; C	hi² = 0.	.18, df =	= 1 (P =	0.67); l <sup>a</sup>	'= 0%			
Test for overall effect	: Z = 0.59	) (P = C	).56)						
									-4 -2 0 2 4
									Favours (intervention) Favours (control)
Test for subgroup dif	ferences	: Chi <sup>2</sup> :	= 5.82,	df = 1 (F	P = 0.02	), <b> </b> ² = 8	2.8%		

Figure 4. Forest plot of post-treatment depression outcome for CBT versus different comparators

## 3.4. Follow up effects

## 3.4.1. Psychoeducation (3 to 12 months)

There were 626 participants from 6 RCTs of psychoeducation who were included in the analysis. Psychoeducation for bipolar disorder had no effect on symptoms of depression at follow up among 4 studies comparing it to usual care and another two studies comparing it to placebo.

# 3.4.2. CBT (3 to 12 months)

There were 482 participants from 6 RCTs of CBT who were included in the analysis. One study (Isasi 2010) had significantly better depression outcome than did the others. The degree of heterogeneity was high (p = 0.0001,  $I^2$  = 80%). CBT for bipolar disorder had no effect on symptoms of depression at follow up among studies comparing it to usual care nor in another study comparing it to placebo(Gliddon 2018; z = 1.99, p = 0.05, SMD = -0.32 [95% CI -0.64, -0.00]).

# 3.4.3. MBCT (12 months)

There were 95 participants from 1 RCTs of MBCT. MBCT for bipolar disorder had no effect on symptoms of depression at follow up (z = 0.90, p = 0.37, SMD = 0.18 [95% CI -0.22, 0.59]).



Figure 5. Forest plot of follow up depression outcome for Psychoeducation versus different comparators

	Intervention Control					1	Std. Mean Difference	Std. Mean Difference			
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl		
2.3.1 CBT versus usu	ual care										
Ball 2006	10.12	10.75	18	10.92	10.39	15	19.8%	-0.07 [-0.76, 0.61]			
Isasi 2010	4.3	5.46	20	17.61	6.75	20	18.6%	-2.13 [-2.92, -1.33]	<b>+</b>		
Lam 2000	6.18	8.44	12	11.56	13.88	11	18.2%	-0.46 [-1.29, 0.37]			
Lam 2003	5.2	5.5	43	5.2	5	44	22.4%	0.00 [-0.42, 0.42]	-		
Weiss 2009	10.1	8.1	25	9.2	7.8	24	21.1%	0.11 [-0.45, 0.67]			
Subtotal (95% CI)			118			114	<b>100.0</b> %	-0.47 [-1.17, 0.23]	$\bullet$		
Heterogeneity: Tau <sup>2</sup> =	= 0.53; C	hi² = 25.	.03, df :	= 4 (P <	0.0001)	);  ² = 84	4%				
Test for overall effect:	Z=1.31	(P = 0.1	19)								
									4 -2 0 2 4		
									Favours [intervention] Favours [control]		

Figure 6. Forest plot of follow up depression outcome for CBT versus different comparators

### 3.5. Publication bias

There was no evidence of publication bias detected overall according to Egger's test (P = 0.493). However, when subgroups of studies were examined based on therapy type, there was an evidence for publication bias for studies of CBT.

#### 3.6. Sensitivity Analysis

In this meta-analysis, we aimed to conduct sensitivity analysis to examine the effect of (i) intervention target, (ii) pre-treatment depression-status; (iii) modality of therapy (self-help,

individual face-to-face therapy, group therapy), (vi) group versus individual therapy, (v) psychological comorbidity at baseline.

As only one study had presence of acute depression as an inclusion criterion it was not possible to run a sensitivity analysis based on this variable. The same applied to the analysis pertaining to presence of psychological comorbidity at baseline.

### 3.6.1. Intervention target

The target of the therapy was clear in 14 of 28 studies. Of these, 3 targeted acute depression, 8 targeted relapse prevention and 3 quality of life. Within these subgroups, there was variability in both therapy type (e.g. CBT, psychoeducation) and comparator (e.g. usual care, placebo). Figure 7 shows the effect sizes for therapies targeting acute depression versus those targeting quality of life and relapse prevention. Given the small number of studies, we were not able to conduct meaningful direct comparison between those targeting acute depression and those targeting other issues. Examining the effect sizes for acute depression trials alone, we note that despite heterogeneity in therapy type and in comparator, the effect sizes are tightly clustered around a small overall effect size (SMD = -0.119 [95% CI -0.280, 0.043]).

### 3.6.2. Pre-treatment depression-status

Pre-treatment depression status was operationalised in two ways: i) whether or not the study inclusion criteria required participants to be depressed; ii) mean depression score for the study sample pre-treatment. As previously stated, analysis according to (i) was not possible because only one study required participants to be acutely depressed. With regard to (ii), the number of studies was too small to allow meta-regression within subgroups according to treatment type and comparator. Instead, we conducted meta-regression on the full set of studies, controlling for the study characteristics of therapy type and comparator. The result showed no significant relationship between baseline depression score and depression outcome post-treatment, when controlling for therapy type and comparator (p = 0.829, 0.003 [-0.026, 0.032]).

#### 3.6.3. Group versus individual therapy

Additional sensitivity analysis showed that there was no significant difference in depression outcome between studies using individual (14 studies; SMD = -0.322 [95% CI -0.529, -0.116]) versus group therapy (6 studies; SMD = -0.352 [95% CI -0.660, -0.044]).



Standardized Mean Difference

Figure 7. Forest plot of sensitivity analysis based upon primary intervention target - post-treatment

#### 4. Discussion

The purpose of this review was to evaluate the effectiveness of psychological interventions for patients with bipolar I or II disorder in reducing the symptoms of depression. We also set out to examine whether intervention target, pre-treatment depression-status, modality of therapy, group versus individual therapy, and psychological comorbidity at baseline impact upon treatment outcomes.

Considering first the evidence for the impact of therapy on depression post-treatment, for CBT and DBT there was low quality evidence of a significant effect on depression post-treatment, particularly in comparison with usual care. At long term follow-up, there was no effect on depression.

Whilst one meta-analysis (Bi-Yu et al., 2016) found no impact of CBT on depression symptoms, our findings support the more recent meta-analyses (Miklowitz, 2021; Chiang et al., 2017) in finding that CBT has benefit upon depressive symptoms post-treatment. This discrepancy may be due to differences in the studies included in the respective meta-

analyses. We note that study numbers in subgroup comparisons in our and other metaanalyses are small, and in our meta-analysis only one study was included that tested DBT. We also note that meta-analyses differed in their definitions around the time point for posttreatment and follow-up outcomes. In this study, we defined post-treatment outcome as the point immediately following the end of the acute treatment phase, and no later than 3 months after the end of treatment. However, this may differ both from other meta-analyses and from the primary outcome points reported in the original study papers. We consider this a strength of the current study in that we are examining depression outcome immediately following treatment, and this is consistent across included studies.

Psychoeducation was not significantly better than usual care and placebo. However, studies comparing psychoeducation to active control found a benefit. We found no significant effects for MBCT, family therapy, and IPSRT at post-treatment. There were only a small number of studies in these analyses, and no data on longer term follow-up.

When covarying for therapy type and comparator, we found no significant link between baseline depression score and depression outcome post-treatment. More studies using similar therapy types and comparators are needed to be able to better look at the relationship between depression status at baseline and outcome.

Given the small number of studies, we were not able to conduct meaningful direct comparison between those targeting acute depression and those targeting other issues. Nevertheless our forest plot revealed the effect sizes for studies targeting acute depression to be tightly clustered around a small overall effect size (SMD = -0.12). This is smaller than the comparable effect size found for unipolar depression, for studies comparing CBT to usual care (SMD = 0.59) (Cuijpers et al., 2013), although it is difficult to make a direct comparison due to heterogeneity amongst the acute depression studies in our analysis in terms of therapy modality and comparator. Considering the effect size for depression outcome we obtained for CBT compared to usual care regardless of therapy target (SMD = -0.51) we note that this is similar to the effect size obtained by Cuijpers and colleagues (2013), although some of the trials in our analysis focussed on relapse, rather than acute depression treatment.

Across all therapy modalities, sensitivity analysis found no significant difference in posttreatment depression outcome between studies using individual and group therapy. Because of limited number of studies it was not possible to separately examine studies in outpatient and inpatient settings.

#### 4.1. Implications

More high-quality randomised controlled trials of psychological interventions for bipolar disorder are required. We would also recommend that studies clearly identify the primary difficulty or difficulties the therapy protocol seeks to target (for example, acute depression, relapse prevention, anxiety). Furthermore, it appears that further development and testing of approaches targeting acute bipolar depression is required.

In terms of reducing depression post-treatment, based upon our analysis the evidence favours CBT, regardless of whether relapse prevention or acute depression is the target, however from the studies we included we cannot determine whether CBT performs better than other therapies, as there were few direct comparisons. This leaves open the question of whether there could be further increases in the efficacy of CBT for bipolar depression if acute depression is the primary focus in the protocol: more studies are needed to address this question. Furthermore, recommended interventions for bipolar depression are largely based on psychological models of unipolar depression: it is possible they may be more effective if derived from evidence-based models of bipolar depression.

# 4.2. Limitations

Our study is subject to some limitations. First, we may not have included all relevant studies as we excluded non-English-language papers and therefore might have missed some relevant trials published in other languages. In addition, some potentially relevant studies were excluded because means and standard deviations of depression scores were not reported in the published paper, and data were unavailable from the authors.

Second, we were limited in our ability to conduct the planned sensitivity analyses. We could not perform an overall analysis of the effect of treatment target because of heterogeneity amongst a small set of studies. Because there were too few separate trials that explicitly selected depressed participants, we were not able to run a sensitivity analysis of depression status at baseline, as measured by stated study inclusion criteria. Also, , our meta-regression looking at the impact of baseline depression was conducted upon a relatively small set of studies with additional degrees of freedom lost due to the need to include covariates. We were not able to look at the impact of treatment modality (remote versus face to face) because too few studies were delivered remotely. In addition, as only one study had presence of acute depression and psychological comorbid condition at baseline as inclusion criteria, we were not able to run a sensitivity analysis using these covariates.

Third, we recognise that our definition of psychological interventions (nonpharmacological treatments whereby the primary hypothesized or intended mechanism of action is via changes in cognitive, behavioural, relational, psychodynamic or interpersonal processes) may exclude some non-medical, relationship-based treatments such as collaborative care.

## 5. Conclusion

Some psychological therapies such as CBT and DBT appear to reduce acute bipolar depression post-treatment, but this effect is not present at longer term follow-up. In the absence of a greater number of high-quality studies however, this conclusion should be viewed with caution. In a small set of studies, the relationship between baseline depression score and depression outcome post-treatment was found not to be significant: there is a need for more research employing similar therapy types and comparators, and defining depression status at baseline, in order to better understand the association between depression status at baseline and outcome. As a result of the small number of studies, we could not directly compare those targeting acute depression to those targeting other issues, nevertheless studies targeting acute depression showed small overall effect sizes that are equivalent or smaller than the equivalent reported for unipolar depression. Further development and testing of interventions specifically targeting bipolar depression is required.

# Funding

This study is partly supported by Ministry of National Education of Turkey.

## **Declarations of interest**

The authors declare no conflicts of interest.

## References

- Ball, J., Mitchell, P., Corry, J., Skillecorn, A., Smith, M., & Malhi, G. (2006). A Randomized Controlled Trial of Cognitive Therapy for Bipolar Disorder. The Journal of Clinical Psychiatry, 67(02), 277-286. doi: 10.4088/jcp.v67n0215
- Beynon, S., Soares-Weiser, K., Woolacott, N., Duffy, S., & Geddes, J. (2008). Psychosocial interventions for the prevention of relapse in bipolar disorder: systematic review of controlled trials. British Journal of Psychiatry, 192(1), 5-11. doi: 10.1192/bjp.bp.107.037887
- Bond, K., & Anderson, I. (2015). Psychoeducation for relapse prevention in bipolar disorder: a systematic review of efficacy in randomized controlled trials. Bipolar Disorders, 17(4), 349-362. doi: 10.1111/bdi.12287
- Cardoso, T., Farias, C., Mondin, T., da Silva, G., Souza, L., & da Silva, R. et al. (2014). Brief Psychoeducation for bipolar disorder: Impact on quality of life in young adults in a 6month follow-up of a randomized controlled trial. Psychiatry Research, 220(3), 896-902. doi: 10.1016/j.psychres.2014.09.013
- Castle, D., Berk, M., Berk, L., Lauder, S., Chamberlain, J., & Gilbert, M. (2007). Pilot of group intervention for bipolar disorder. International Journal Of Psychiatry In Clinical Practice, 11(4), 279-284. doi: 10.1080/13651500701246088
- Castle, D., White, C., Chamberlain, J., Berk, M., Berk, L., & Lauder, S. et al. (2010). Groupbased psychosocial intervention for bipolar disorder: randomised controlled trial. British Journal Of Psychiatry, 196(5), 383-388. doi: 10.1192/bjp.bp.108.058263
- Chen, R., Zhu, X., Capitão, L., Zhang, H., Luo, J., & Wang, X. et al. (2018). Psychoeducation for psychiatric inpatients following remission of a manic episode in bipolar I disorder: A randomized controlled trial. Bipolar Disorders, 21(1), 76-85. doi: 10.1111/bdi.12642
- Chiang, K., Tsai, J., Liu, D., Lin, C., Chiu, H., & Chou, K. (2017). Efficacy of cognitive-behavioral therapy in patients with bipolar disorder: A meta-analysis of randomized controlled trials. PLOS ONE, 12(5), e0176849. doi: 10.1371/journal.pone.0176849
- Costa, R., Cheniaux, E., Rosaes, P., Carvalho, M., Freire, R., & Versiani, M. et al. (2011). The effectiveness of cognitive behavioral group therapy in treating bipolar disorder: a randomized controlled study. Revista Brasileira De Psiquiatria, 33(2), 144-149. doi: 10.1590/s1516-44462011000200009
- Crump, C., Sundquist, K., Winkleby, M., & Sundquist, J. (2013). Comorbidities and Mortality in Bipolar Disorder. JAMA Psychiatry, 70(9), 931. doi: 10.1001/jamapsychiatry.2013.1394
- Cuijpers, P., Berking, M., Andersson, G., Quigley, L., Kleiboer, A., & Dobson, K. (2013). A Meta-Analysis of Cognitive-Behavioural Therapy for Adult Depression, Alone and in Comparison with other Treatments. The Canadian Journal Of Psychiatry, 58(7), 376-385. doi: 10.1177/070674371305800702

- Darke, S. (2016). Psychosocial Interventions for Mental and Substance Use Disorders: A Framework for Establishing Evidence-Based Standards MARY JANE ENGLAND, ADRIENNE STITH BUTLER & MONICA L. GONZALEZ (EDITORS); COMMITTEE ON DEVELOPING EVIDENCE-BASED STANDARDS FOR PSYCHOSO. Drug And Alcohol Review, 35(4), 503-503. doi: 10.1111/dar.12373
- Deckersbach, T., Peters, A., Shea, C., Gosai, A., Stange, J., & Peckham, A. et al. (2018).
  Memory performance predicts response to psychotherapy for depression in bipolar disorder: A pilot randomized controlled trial with exploratory functional magnetic resonance imaging. Journal Of Affective Disorders, 229, 342-350. doi: 10.1016/j.jad.2017.12.041
- Docteur, A., Mirabel-Sarron, C., Kaya Lefèvre, H., Sala, L., Husky, M., Swendsen, J., & Gorwood, P. (2020). Role of autobiographical memory in the impact of MBCT on dysfunctional attitudes, depressive symptoms and anxiety in bipolar I patients. Journal Of Affective Disorders, 276, 907-913. doi: 10.1016/j.jad.2020.07.072
- D'Souza, R., Piskulic, D., & Sundram, S. (2010). A brief dyadic group based Psychoeducation program improves relapse rates in recently remitted bipolar disorder: A pilot randomised controlled trial. Journal Of Affective Disorders, 120(1-3), 272-276. doi: 10.1016/j.jad.2009.03.018
- Eroglu, M., Karakus, G., & Tamam, L. (2013). Bipolar Bozukluk Ve Özkıyım / Bipolar Disorder and Suicide. Dusunen Adam: The Journal Of Psychiatry And Neurological Sciences. doi: 10.5350/dajpn2013260203
- Faltinsen, E., Todorovac, A., Hróbjartsson, A., Gluud, C., Kongerslev, M., Simonsen, E., &
  Storebø, O. (2019). Placebo, usual care and wait-list interventions for all mental health disorders. Cochrane Database Of Systematic Reviews. doi: 10.1002/14651858.mr000050
- Faria, A., Jansen, K., Dias de Mattos Souza, L., Amaral Tavares Pinheiro, K., de Azevedo Cardoso, T., Azevedo da Silva, R., & Pinheiro, R. (2014). The influence of Psychoeducation on regulating biological rhythm in a sample of patients with bipolar II disorder: a randomized clinical trial. Psychology Research And Behavior Management, 167. doi: 10.2147/prbm.s52352
- Faridhosseini, F., Baniasadi, M., Reza Fayyazi Bordbar, M., Pourgholami, M., Ahrari, S. & Asgharipour., N. (2017). Effectiveness of Psychoeducational Group Training on Quality of Life and Recurrence of Patients with Bipolar Disorder. Iran J Psychiatry, 12:1: 21-28
- Gliddon, E., Cosgrove, V., Berk, L., Lauder, S., Mohebbi, M., & Grimm, D. et al. (2018). A randomized controlled trial of MoodSwings 2.0: An internet-based self-management program for bipolar disorder. Bipolar Disorders, 21(1), 28-39. doi: 10.1111/bdi.12669
- Higgins, J. (2003). Measuring inconsistency in meta-analyses. BMJ, 327(7414), 557-560. doi: 10.1136/bmj.327.7414.557

- Higgins, J., Altman, D., Gotzsche, P., Juni, P., Moher, D., & Oxman, A. et al. (2011). The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ, 343(oct18 2), d5928-d5928. doi: 10.1136/bmj.d5928
- Isasi, A., Echeburúa, E., Limiñana, J., & González-Pinto, A. (2010). How effective is a psychological intervention program for patients with refractory bipolar disorder? A randomized controlled trial. Journal Of Affective Disorders, 126(1-2), 80-87. doi: 10.1016/j.jad.2010.03.026
- Jones, S., Riste, L., Robinson, H., Holland, F., Peters, S., & Hartwell, R. et al. (2019). Feasibility and acceptability of integrated psychological therapy versus treatment as usual for people with bipolar disorder and co-morbid alcohol use: A single blind randomised controlled trial. Journal Of Affective Disorders, 256, 86-95. doi: 10.1016/j.jad.2019.05.038
- Judd, L., Akiskal, H., Schettler, P., Endicott, J., Maser, J., & Solomon, D. et al. (2002). The Long-term Natural History of the Weekly Symptomatic Status of Bipolar I Disorder. Archives Of General Psychiatry, 59(6), 530. doi: 10.1001/archpsyc.59.6.530
- Judd, L., & Akiskal, H. (2003). Depressive episodes and symptoms dominate the longitudinal course of bipolar disorder. Current Psychiatry Reports, 5(6), 417-418. doi: 10.1007/s11920-003-0077-2
- Kemp, D., Gao, K., Chan, P., Ganocy, S., Findling, R., & Calabrese, J. (2010). Medical comorbidity in bipolar disorder: relationship between illnesses of the endocrine/metabolic system and treatment outcome. Bipolar Disorders, 12(4), 404-413. doi: 10.1111/j.1399-5618.2010.00823.x
- Krishnan, K. (2005). Psychiatric and Medical Comorbidities of Bipolar Disorder. Psychosomatic Medicine, 67(1), 1-8. doi: 10.1097/01.psy.0000151489.36347.18
- Lam, D., Bright, J., Jones, S., Hayward, P., Schuck, N., Chisholm, D., & Sham, P. (2000). Cognitive Therapy for Bipolar Illness—A Pilot Study of Relapse Prevention. Cognitive Therapy And Research, 24(5), 503-520. doi: 10.1023/a:1005557911051
- Lam, D., Watkins, E., Hayward, P., Bright, J., Wright, K., & Kerr, N. et al. (2003). A Randomized Controlled Study of Cognitive Therapy for Relapse Prevention for Bipolar Affective Disorder. Archives Of General Psychiatry, 60(2), 145. doi: 10.1001/archpsyc.60.2.145
- Laursen, T. (2011). Life expectancy among persons with schizophrenia or bipolar affective disorder. Schizophrenia Research, 131(1-3), 101-104. doi: 10.1016/j.schres.2011.06.008
- Lin, C., Huang, Y., Huang, K., Wu, S., Chang, Y., & Yeh, H. et al. (2020). A Randomized Controlled Trial of Transcultural Validation of Group-Based Psychosocial Intervention for Patients with Bipolar Disorder. Psychiatry Research, 290, 113139. doi: 10.1016/j.psychres.2020.113139

- McIntyre, R., Konarski, J., Soczynska, J., Wilkins, K., Panjwani, G., & Bouffard, B. et al. (2006).
  Medical Comorbidity in Bipolar Disorder: Implications for Functional Outcomes and
  Health Service Utilization. Psychiatric Services, 57(8), 1140-1144. doi:
  10.1176/ps.2006.57.8.1140
- Merikangas, K., Jin, R., He, J., Kessler, R., Lee, S., & Sampson, N. et al. (2011). Prevalence and Correlates of Bipolar Spectrum Disorder in the World Mental Health Survey Initiative. Archives Of General Psychiatry, 68(3), 241. doi: 10.1001/archgenpsychiatry.2011.12
- Miklowitz, D., Simoneau, T., George, E., Richards, J., Kalbag, A., Sachs-Ericsson, N., &
  Suddath, R. (2000). Family-focused treatment of bipolar disorder: 1-year effects of a
  Psychoeducational program in conjunction with pharmacotherapy. Biological Psychiatry, 48(6), 582-592. doi: 10.1016/s0006-3223(00)00931-8
- Miklowitz, J. (2007). Psychosocial Treatments for Bipolar Depression: A 1-Year Randomized Trial From the Systematic Treatment Enhancement Program. Yearbook Of Psychiatry And Applied Mental Health, 2008, 51-53. doi: 10.1016/s0084-3970(08)70658-3
- Miklowitz, D., Efthimiou, O., Furukawa, T., Scott, J., McLaren, R., Geddes, J., & Cipriani, A. (2021). Adjunctive Psychotherapy for Bipolar Disorder. JAMA Psychiatry, 78(2), 141. doi: 10.1001/jamapsychiatry.2020.2993
- Morriss, R., Lobban, F., Riste, L., Davies, L., Holland, F., & Long, R. et al. (2016). Clinical effectiveness and acceptability of structured group Psychoeducation versus optimised unstructured peer support for patients with remitted bipolar disorder (PARADES): a pragmatic, multicentre, observer-blind, randomised controlled superiority trial. The Lancet Psychiatry, 3(11), 1029-1038. doi: 10.1016/s2215-0366(16)30302-9
- Oud, M., Mayo-Wilson, E., Braidwood, R., Schulte, P., Jones, S., & Morriss, R. et al. (2016). Psychological interventions for adults with bipolar disorder: systematic review and metaanalysis. British Journal Of Psychiatry, 208(3), 213-222. doi: 10.1192/bjp.bp.114.157123
- Perich, T., Manicavasagar, V., Mitchell, P., Ball, J., & Hadzi-Pavlovic, D. (2012). A randomized controlled trial of mindfulness-based cognitive therapy for bipolar disorder. Acta Psychiatrica Scandinavica, 127(5), 333-343. doi: 10.1111/acps.12033
- Perlis, R., Ostacher, M., Patel, J., Marangell, L., Zhang, H., & Wisniewski, S. et al. (2006).
  Predictors of Recurrence in Bipolar Disorder: Primary Outcomes From the Systematic
  Treatment Enhancement Program for Bipolar Disorder (STEP-BD). FOCUS, 4(4), 553-561.
  doi: 10.1176/foc.4.4.553
- Pini, S., Cassano, G., Simonini, E., Savino, M., Russo, A. and Montgomery, S., 1997. Prevalence of anxiety disorders comorbidity in bipolar depression, unipolar depression and dysthymia. Journal of Affective Disorders, 42(2-3), pp.145-153.
- Porter, R., Inder, M., Douglas, K., Moor, S., Carter, J., Frampton, C., & Crowe, M. (2019). Improvement in cognitive function in young people with bipolar disorder: Results from participants in an 18-month randomised controlled trial of adjunctive psychotherapy.

Australian & New Zealand Journal Of Psychiatry, 54(3), 272-281. doi: 10.1177/0004867419887794

- Rihmer, Z., Barsi, J., Arató, M., & Demeter, E. (1990). Suicide in subtypes of primary major depression. Journal Of Affective Disorders, 18(3), 221-225. doi: 10.1016/0165-0327(90)90039-b
- Schmitz, J., Averill, P., Sayre, S., McCleary, P., Moeller, F., & Swann, A. (2002). Cognitive– Behavioral Treatment of Bipolar Disorder and Substance Abuse: A Preliminary Randomized Study. Addictive Disorders & Their Treatment, 1(1), 17-24. doi: 10.1097/00132576-200205000-00004
- Schünemann H, Brożek J, Guyatt G, Oxman A, editors. GRADE handbook for grading quality of evidence and strength of recommendations. Updated October 2013. The GRADE Working Group, 2013. Available from guidelinedevelopment.org/handbook
- Smith, D., Griffiths, E., Poole, R., di Florio, A., Barnes, E., & Kelly, M. et al. (2011). Beating Bipolar: exploratory trial of a novel internet-based Psychoeducational treatment for bipolar disorder. Bipolar Disorders, 13(5-6), 571-577. doi: 10.1111/j.1399-5618.2011.00949.x
- Tidemalm, D., Haglund, A., Karanti, A., Landén, M., & Runeson, B. (2014). Attempted Suicide in Bipolar Disorder: Risk Factors in a Cohort of 6086 Patients. Plos ONE, 9(4), e94097. doi: 10.1371/journal.pone.0094097
- Van Dijk, S., Jeffrey, J., & Katz, M. (2013). A randomized, controlled, pilot study of dialectical behavior therapy skills in a Psychoeducational group for individuals with bipolar disorder. Journal Of Affective Disorders, 145(3), 386-393. doi: 10.1016/j.jad.2012.05.054
- Vieta, E., Colom, F., Corbella, B., Martínez-Arán, A., Reinares, M., Benabarre, A., & Gastó, C. (2001). Clinical correlates of psychiatric comorbidity in bipolar I patients. Bipolar Disorders, 3(5), 253-258. doi: 10.1034/j.1399-5618.2001.30504.x
- Weiss, R., Griffin, M., Kolodziej, M., Greenfield, S., Najavits, L., & Daley, D. et al. (2007). A Randomized Trial of Integrated Group Therapy Versus Group Drug Counseling for Patients With Bipolar Disorder and Substance Dependence. American Journal Of Psychiatry, 164(1), 100-107. doi: 10.1176/ajp.2007.164.1.100
- Weiss, R., Griffin, M., Jaffee, W., Bender, R., Graff, F., Gallop, R., & Fitzmaurice, G. (2009). A "community-friendly" version of integrated group therapy for patients with bipolar disorder and substance dependence: A randomized controlled trial. Drug And Alcohol Dependence, 104(3), 212-219. doi: 10.1016/j.drugalcdep.2009.04.018
- Ye, B., Jiang, Z., Li, X., Cao, B., Cao, L., & Lin, Y. et al. (2016). Effectiveness of cognitive behavioral therapy in treating bipolar disorder: An updated meta-analysis with randomized controlled trials. Psychiatry And Clinical Neurosciences, 70(8), 351-361. doi: 10.1111/pcn.12399

Zaki, N., Awaad, M., Elbatrawy, A., Elmissiry, M., & Zahran, N. (2014). Effectiveness of a behavioral family Psychoeducational program for Egyptian patients with bipolar disorder and their caregivers. Middle East Current Psychiatry, 21(4), 212-221. doi: 10.1097/01.xme.0000453069.21124.74